Stay updated on Tilsotolimod Combo Therapy Clinical Trial
Sign up to get notified when there's something new on the Tilsotolimod Combo Therapy Clinical Trial page.

Latest updates to the Tilsotolimod Combo Therapy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a Phase 2 study of tilsotolimod in combination with immunotherapy drugs, including detailed inclusion and exclusion criteria. The only notable addition is the mention of collaborators Bristol-Myers Squibb and a revision update to v2.15.0.SummaryDifference40%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Tilsotolimod Combo Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tilsotolimod Combo Therapy Clinical Trial page.